Menu
Not yet recruiting NCT07344584

A Prospective Pilot Study to Evaluate Safety and Effectiveness of GP0122 and GP0124 for Correction of Lines and Wrinkles in the Cheek Area

No phase Interventional Wrinkle Reduction

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: GP0122, GP0124.
Who it may be relevant to
Registry conditions: Wrinkle Reduction. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The primary objective of the study is to evaluate the safety of GP0122 and GP0124 for the correction of lines and wrinkles in the cheek area.

Interventions

  • Device GP0122
    Injectable gel.
  • Device GP0124
    Injectable gel.

Primary outcome measures

  • Number of Participants With all Adverse Events (AEs) [Time frame: From Day 1 up to last visit (Up to 12 months)]
  • Number of Participants With Post-Treatment Responses as Assessed Using Subject Diary Data [Time frame: From Day 1 up to Day 28]
  • Participant's Pain Assessment Using Numeric Pain Scale (NPS) Immediately Post Treatment and 30 Minutes Post Treatment [Time frame: Immediately and 30 minutes after each treatment]
Secondary outcome measures (2)
  • Responder Rates Based on the Treating Investigator's Live Assessment of the GCWS at Rest at Months 3, 6, 9 and 12 [Time frame: At Months 3, 6, 9 and 12]
  • Responder Rates Based on the Treating Investigator's Live Assessment of the CSQS-CL at Rest at Months 3, 6, 9 and 12 [Time frame: At Months 3, 6, 9 and 12]

Eligibility criteria

Inclusion Criteria: Adult males or non-pregnant, non-breastfeeding adult females.

  • Participants with a GCWS At Rest score of Moderate or Severe on EACH side of the face, or Participants with a CSQS-CL score of Moderate, Severe, or Very severe on EACH side of the face.
  • Intent to undergo treatment for correction of lines and wrinkles in the cheek region.
  • Willing to abstain from any other facial plastic, surgical or cosmetic procedures in the cheek area for the duration of the study (e.g., laser or chemical resurfacing, needling, facelift, lifting threads, radiofrequency etc.).

Inclusion criteria 4-5 apply only to female participants of childbearing potential:

  • Agrees to use an acceptable form of effective birth control for the duration of the study and is willing to take a urine pregnancy test (UPT) at screening, baseline and prior to receiving any study treatment.
  • Negative UPT at the screening and baseline visits.

Exclusion criteria

  • Known/previous allergy or hypersensitivity.
  • Known/previous allergy or hypersensitivity to local anesthetics.
  • Previous facial surgery (e.g., facelift) in the treatment area that in the Treating Investigator´s opinion.
  • Any previous aesthetic procedures or implants in the treatment area.
  • Presence of any disease or lesions in the treatment area.
  • An underlying known disease, a surgical or medical condition that would expose the participant to undue risk.
  • Use of concomitant medication that have the potential to prolong bleeding times.
  • Presence of any condition or situation, which in the opinion of the Treating Investigator makes the subject unable to complete the study per protocol.
  • Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT07344584 · 43CASH2210

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗